Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$18.03 USD
+0.42 (2.39%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $17.55 -0.48 (-2.66%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MCRB 18.03 +0.42(2.39%)
Will MCRB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MCRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MCRB
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross
MCRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
Other News for MCRB
Calm After Storm appears for MCRB after 1.21% move
Is MCRB building bullish momentum? Crossed Above 50 Day Moving Average shows up after rallying 10.9%
Is MCRB signaling selling opportunity? Fell Below 50 Day Moving Average shows up after sinking 1.38%
Is MCRB building bullish momentum? 50 Day Moving Average Support shows up after crashing 9.45%
MCRB forms 1,2,3 Pullback Bullish on September 11